The underlying mechanism is linked to the accumulation of reactive oxygen species (ROS) following ALDH2 inhibition. The findings suggest that APC-deficient cells rely on ALDH2 to manage metabolic stress, making them particularly vulnerable when this pathway is disrupted. In contrast, cells with intact APC function show reduced sensitivity to ALDH2 inhibition, highlighting a selective dependency that could be exploited therapeutically. As an enzyme, ALDH2 represents a more accessible target for drug development compared to many genetic drivers of cancer. These results contribute to a growing body of work focused on identifying metabolic vulnerabilities in cancer cells.

Source: The Herald March 23, 2026 22:58 UTC